tradingkey.logo

Lucid Diagnostics Inc

LUCD

1.090USD

+0.020+1.87%
Close 09/19, 16:00ETQuotes delayed by 15 min
110.99MMarket Cap
LossP/E TTM

Lucid Diagnostics Inc

1.090

+0.020+1.87%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
104 / 207
Overall Ranking
230 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
3.708
Target Price
+246.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1052.79% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.35M.
Undervalued
The company’s latest PE is -1.15, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 49.62M shares, increasing 14.07% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.13M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.28.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.21, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.16M, representing a year-over-year increase of 19.16%, while its net profit experienced a year-over-year increase of 28.32%.

Score

Industry at a Glance

Previous score
6.21
Change
0

Financials

6.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

8.93

Operational Efficiency

2.77

Growth Potential

4.78

Shareholder Returns

7.57

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -1.13, which is -25.27% below the recent high of -0.84 and 5.95% above the recent low of -1.06.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.33, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Lucid Diagnostics Inc is 3.00, with a high of 7.75 and a low of 2.50.

Score

Industry at a Glance

Previous score
8.33
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts
Buy
Current Rating
3.708
Target Price
+246.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
Lucid Diagnostics Inc
LUCD
6
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.58, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.41 and the support level at 0.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.58
Change
0

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.037
Neutral
RSI(14)
47.215
Neutral
STOCH(KDJ)(9,3,3)
21.516
Neutral
ATR(14)
0.098
High Vlolatility
CCI(14)
-45.613
Neutral
Williams %R
84.897
Oversold
TRIX(12,20)
0.020
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
1.072
Buy
MA10
1.097
Sell
MA20
1.170
Sell
MA50
1.100
Sell
MA100
1.173
Sell
MA200
1.159
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 45.86%, representing a quarter-over-quarter decrease of 4.73%. The largest institutional shareholder is The Vanguard, holding a total of 4.13M shares, representing 3.01% of shares outstanding, with 218.20% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
PAVmed Inc
31.30M
--
The Vanguard Group, Inc.
Star Investors
888.87K
+58.47%
Masters Capital Management, L.L.C.
2.73M
--
Geode Capital Management, L.L.C.
303.18K
+8.47%
Aklog (Lishan)
1.47M
-4.86%
McGrath (Dennis M)
1.32M
-5.38%
Ayrton Capital LLC
1.20M
+7216.46%
O'Neil (Shaun)
826.76K
-5.70%
Luminus Management, L.L.C.
456.64K
-55.09%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.19, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.19
Change
0
Beta vs S&P 500 index
1.23
VaR
--
240-Day Maximum Drawdown
+40.69%
240-Day Volatility
+92.04%
Return
Best Daily Return
60 days
+11.29%
120 days
+19.55%
5 years
--
Worst Daily Return
60 days
-19.69%
120 days
-24.24%
5 years
--
Sharpe Ratio
60 days
-0.26
120 days
-0.53
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+40.69%
3 years
+70.48%
5 years
--
Return-to-Drawdown Ratio
240 days
+0.65
3 years
-0.20
5 years
--
Skewness
240 days
-0.23
3 years
+0.24
5 years
--
Volatility
Realised Volatility
240 days
+92.04%
5 years
--
Standardised True Range
240 days
+7.94%
5 years
--
Downside Risk-Adjusted Return
120 days
-63.97%
240 days
-63.97%
Maximum Daily Upside Volatility
60 days
+53.26%
Maximum Daily Downside Volatility
60 days
+55.18%
Liquidity
Average Turnover Rate
60 days
+1.29%
120 days
+1.39%
5 years
--
Turnover Deviation
20 days
+28.16%
60 days
+83.29%
120 days
+98.00%

Peer Comparison

Healthcare Equipment & Supplies
Lucid Diagnostics Inc
Lucid Diagnostics Inc
LUCD
5.85 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI